China Isotope & Radiation (1763) Fundamentals 2026 — P/E 14.6x, Revenue Analysis | SniperIQ

6.86 on the HKSE. This SniperIQ fundamentals page covers China Isotope & Radiation's valuation (P/E 14.6x, P/B 0.9x), profitability (net margin 4.6%), revenue (¥7.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is China Isotope & Radiation's market cap?

China Isotope & Radiation (1763) has a market capitalization of approximately HK$5.4B, trading at HK

6.86 on the HKSE. Market cap moves with the live share price.

What is China Isotope & Radiation's P/E ratio?

China Isotope & Radiation's trailing twelve-month P/E ratio is 14.6x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is China Isotope & Radiation?

China Isotope & Radiation runs a net profit margin of 4.6%, a gross margin of 50.3%, and an operating margin of 13.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does China Isotope & Radiation generate?

China Isotope & Radiation reported revenue of ¥7.0B for fiscal year 2025, with net income of ¥319M and earnings per share (EPS) of 1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does China Isotope & Radiation pay a dividend?

China Isotope & Radiation offers a trailing dividend yield of about 2.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is China Isotope & Radiation financially healthy?

China Isotope & Radiation carries a debt-to-equity ratio of 0.52x and a current ratio of 1.76x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is China Isotope & Radiation a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Isotope & Radiation (1763) the key facts are: market cap HK$5.4B, P/E 14.6x, revenue ¥7.0B, 52-week range 15.2-25. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.